List of Excipients in Branded Drug FERRIPROX

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Chiesi USA Inc	FERRIPROX	deferiprone	10122-100	CELLULOSE, MICROCRYSTALLINE
Chiesi USA Inc	FERRIPROX	deferiprone	10122-100	HYPROMELLOSE 2910
Chiesi USA Inc	FERRIPROX	deferiprone	10122-100	MAGNESIUM STEARATE
Chiesi USA Inc	FERRIPROX	deferiprone	10122-100	POLYETHYLENE GLYCOL 3350
Chiesi USA Inc	FERRIPROX	deferiprone	10122-100	SILICON DIOXIDE
Chiesi USA Inc	FERRIPROX	deferiprone	10122-100	TITANIUM DIOXIDE
Chiesi USA Inc	FERRIPROX	deferiprone	10122-101	FD&C YELLOW NO. 6

Ferriprox Excipient Strategy and Commercial Opportunities

Last updated: August 10, 2026

Ferriprox, the deferiprone iron chelator, has a relatively simple oral product platform: 500 mg and 1,000 mg film-coated tablets plus a 100 mg/mL oral solution. The main excipient opportunities are pediatric and adherence-oriented rather than basic reformulation. Commercially attractive concepts include improved taste masking, lower-volume liquid dosing, stable multidose packaging, dispersible tablets, and differentiated formulations that reduce administration burden without changing deferiprone exposure.

What formulations does Ferriprox currently have?

Ferriprox is marketed as deferiprone in immediate-release oral dosage forms. The U.S. product includes film-coated tablets and an oral solution. The labeled indication is transfusional iron overload associated with thalassemia syndromes when current chelation therapy is inadequate [1].

Product	Strength	Dosage form	Key commercial role
Ferriprox tablet	500 mg	Film-coated, scored tablet	Flexible adult and adolescent dosing
Ferriprox tablet	1,000 mg	Film-coated, scored tablet	Lower tablet burden at high doses
Ferriprox oral solution	100 mg/mL	Multidose liquid	Pediatric, dysphagia, and dose-weight flexibility

The labeled deferiprone regimen can require administration three times daily or twice daily depending on the prescribed total daily dose and formulation. At 75 mg/kg/day, a 60 kg patient receives 4,500 mg per day. That dose equals nine 500 mg tablets, approximately four and a half 1,000 mg tablets, or 45 mL of a 100 mg/mL solution. Administration burden is therefore a material product-design issue [1].

What excipients are used in Ferriprox?

The Ferriprox oral solution uses a short excipient system centered on glycerol, hydroxyethylcellulose, sodium metabisulfite, and purified water. The tablets use conventional direct-compression and film-coating excipients, including microcrystalline cellulose, crospovidone, povidone, colloidal silicon dioxide, magnesium stearate, and coating components [1].

Ferriprox excipient profile

Formulation attribute	Current design implication
Glycerol in oral solution	Provides bulk, sweetness, mouthfeel, and solvent functionality
Hydroxyethylcellulose	Controls viscosity and suspension or solution handling characteristics
Sodium metabisulfite	Supports oxidative stability but creates a sulfite-sensitivity labeling consideration
Purified water	Aqueous multidose vehicle requiring microbial and container-closure control
Microcrystalline cellulose	Tablet diluent and compaction aid
Crospovidone	Immediate-release disintegration
Povidone	Binder
Colloidal silicon dioxide	Flow and processing aid
Magnesium stearate	Lubricant
Film-coat polymers and pigments	Swallowability, appearance, identification, and handling

The product does not depend on a technically complex delivery platform such as a lipid system, osmotic system, depot injection, or biologic stabilizer matrix. That reduces manufacturing complexity but also limits the ability to create defensible differentiation through routine excipient substitution.

Which excipient risks matter most for deferiprone?

The key risks are oxidative stability, sulfite sensitivity, taste, microbial control, and dose-volume management.

Oxidative stability and metal control

Deferiprone is a bidentate iron chelator. The formulation must be evaluated for chemical stability in the presence of trace metals, oxygen, light, and reactive packaging surfaces. Excipients with peroxide impurities, metal contamination, or variable redox behavior can create development problems even when they are pharmaceutically common.

A reformulation program should control:

• Peroxide levels in polymers, surfactants, and povidone grades
• Elemental impurities in excipients and packaging components
• Oxygen ingress through bottles, liners, and dispensing devices
• Light exposure during storage and use
• Extractables and leachables from multidose containers
• Compatibility with oral syringes and dosing cups

The most commercially credible excipient strategy is a validated stability package rather than an ingredient novelty claim. A formulation with equivalent bioavailability, longer in-use stability, and simpler storage can generate more value than one based on an uncommon excipient.

Sodium metabisulfite and hypersensitivity

Sodium metabisulfite is included in the Ferriprox oral solution as an antioxidant. Sulfites can cause hypersensitivity reactions in susceptible patients and must be reflected in product labeling and risk communications. Removing or replacing the sulfite could create a meaningful product advantage if stability remains acceptable.

Potential alternatives include:

• Oxygen-reduced filling and nitrogen headspace
• Low-peroxide excipient grades
• Chelating agents used within regulatory and compatibility limits
• Light-protective packaging
• More protective container-closure systems
• Antioxidant systems that avoid sulfite exposure

A sulfite-free liquid would require comparative stability, impurity, microbiological, and clinical bridging work. The commercial value would be highest in pediatric patients and markets where sulfite avoidance is a recognized prescribing or caregiver concern.

How can Ferriprox taste masking create commercial value?

Taste is a central weakness of many high-dose oral chelators. The current oral solution provides dosing flexibility, but a 60 kg patient taking 45 mL per day faces a substantial liquid burden. Deferiprone’s active ingredient can create bitterness or metallic taste, making palatability a practical adherence issue.

High-value taste-masking approaches

A developer could pursue:

1. Ion-exchange resin complexes
   Deferiprone could be associated with a pharmaceutical-grade resin and released after ingestion. This approach can reduce immediate taste perception but must preserve dose uniformity and release.

2. Polymer microencapsulation
   Microencapsulation can shield the drug in the mouth while allowing rapid gastrointestinal release. Particle size, redispersibility, and dose reproducibility are critical.

3. Multiparticulate granules
   Coated granules or sprinkles could be administered with soft food or a compatible beverage. This format may improve pediatric acceptance but requires clear administration instructions.

4. Flavored oral solution
   Flavor optimization is the lowest-complexity path, but flavor alone may not overcome the taste of a high-concentration chelator.

5. Orally disintegrating or dispersible tablets
   These formats could reduce swallowing difficulty but may increase taste exposure unless coated particles or a multiparticulate design is used.

A useful commercial target would be a formulation that maintains the 100 mg/mL dose concentration while reducing bitterness and permitting administration in a smaller, measured volume. A 150 mg/mL or 200 mg/mL liquid could reduce volume further, but higher concentration may worsen taste, viscosity, precipitation, and dose-uniformity risks.

What pediatric formulation opportunities exist for Ferriprox?

The pediatric opportunity is strongest in dosing accuracy, palatability, and caregiver handling. Thalassemia is a chronic disease requiring repeated administration over years. Small improvements in daily administration can have cumulative clinical and commercial value.

Pediatric product concepts

Concept	Benefit	Principal development issue
Sulfite-free oral solution	Removes a labeled excipient concern	Oxidative stability
Higher-concentration liquid	Reduces daily volume	Solubility, taste, viscosity
Ready-to-use unit-dose sachets	Improves portability and dose control	Packaging cost and waste
Oral powder for reconstitution	Extends shelf life and lowers shipping burden	Reconstitution uniformity
Coated granules	Masks taste and supports flexible dosing	Release and dose recovery
Dispersible tablet	Reduces liquid dependence	Palatability and dispersion
Age-banded dosing device	Improves administration accuracy	Device validation and market complexity

A formulation with a validated oral syringe and age-specific dosing instructions could create value without changing the drug product substantially. The dosing device should be compatible with the formulation, resist extractables, and allow accurate measurement at low volumes. A dosing cup is less precise for pediatric use and may be commercially weaker.

What formulation patents could protect a Ferriprox follow-on product?

The strongest patent opportunities would generally arise from a specific, measurable technical result rather than a generic excipient list.

Potential claim categories

• Deferiprone liquid containing a defined antioxidant system
• Sulfite-free deferiprone formulation with specified impurity limits
• High-concentration aqueous deferiprone composition
• Taste-masked deferiprone particles with defined release behavior
• Deferiprone-resin complex or coated multiparticulate
• Stable formulation with defined peroxide and metal limits
• Container-closure system that improves in-use stability
• Oral dosage form with a specified dissolution profile
• Pediatric formulation administered with a validated dosing device
• Co-packaged formulation and administration system

A formulation patent should connect composition to performance. Claims limited to broad excipient classes are vulnerable to obviousness challenges, especially where the excipients are standard pharmaceutical ingredients. Stronger protection can come from a narrow combination that delivers an unexpected stability, palatability, dissolution, or in-use result.

Patent and regulatory pathway

A follow-on product could be pursued through an ANDA if it is pharmaceutically equivalent and meets the applicable bioequivalence requirements. A materially different dosage form, concentration, excipient system, or delivery technology may require a 505(b)(2) strategy in the United States, depending on the proposed product and FDA determination [2].

For a 505(b)(2) product, the commercial plan should separate:

• Drug substance sameness
• Exposure and bioequivalence
• Clinical relevance of excipient changes
• Pediatric safety and palatability
• Labeling differences
• Listed-patent and exclusivity issues
• Device or container-closure requirements

Ferriprox received orphan-drug status, and the original U.S. approval created a period of orphan exclusivity. Orphan exclusivity is distinct from patent protection and does not prevent all subsequent development, particularly where a product uses a different route, formulation, or legally available indication pathway [1, 3].

What is the Orange Book and generic-entry position for Ferriprox?

Ferriprox is an NDA product, while potential generic competitors would generally seek approval under an abbreviated pathway if they can satisfy equivalence requirements. The principal commercial barriers are likely to include chronic disease market access, monitoring requirements, manufacturing quality, and physician confidence, in addition to any active patent or regulatory exclusivity rights listed for the product.

The drug carries a serious risk of neutropenia and agranulocytosis. FDA labeling requires blood-count monitoring and interruption or discontinuation procedures for specified neutrophil abnormalities [1]. A generic or follow-on sponsor must therefore compete against the full treatment-management burden, not only tablet price.

A differentiated liquid or pediatric product may avoid direct price competition with a conventional tablet ANDA. Its value proposition would instead rest on:

• Better adherence
• More accurate weight-based dosing
• Improved taste
• Lower dose volume
• Reduced caregiver burden
• Greater use in younger patients
• Better persistence in patients who cannot swallow tablets

How strong is the Ferriprox formulation patent opportunity?

The formulation patent opportunity is moderate, with the strongest prospects in a clinically meaningful product improvement. A basic immediate-release tablet using standard fillers, binders, disintegrants, and lubricants is unlikely to create a durable moat by itself.

Relative strength of potential strategies

Strategy	Technical differentiation	Patent potential	Commercial attractiveness
Conventional tablet excipient substitution	Low	Low	Low
Flavor-only oral solution	Low to moderate	Low	Moderate
Sulfite-free stable solution	Moderate	Moderate to high	Moderate to high
High-concentration liquid	Moderate	Moderate	High if palatable
Taste-masked multiparticulate	High	High	High
Unit-dose pediatric liquid	Moderate	Moderate	Moderate
Novel sustained-release product	High	High	Uncertain because dosing and exposure may change
Device-enabled dosing system	Moderate	Moderate	Moderate

A long-acting formulation could reduce dosing frequency, but it carries greater clinical and regulatory risk. Deferiprone dosing is tied to iron burden management and tolerability. Changing the exposure profile could require more than a routine bioequivalence package.

Which commercial opportunities are most attractive?

The highest-value opportunities are products that address daily use rather than merely duplicate Ferriprox tablets.

1. Palatable pediatric liquid

A stable, sulfite-free, taste-masked 100 mg/mL liquid could compete on adherence and caregiver usability. This is the clearest opportunity for an improved product with a differentiated excipient platform.

2. Higher-concentration oral solution

A 150 mg/mL or 200 mg/mL formulation could materially lower dose volume. The product would need strong taste masking, accurate dosing hardware, and robust in-use stability.

3. Sprinkle or multiparticulate formulation

Coated granules could support children and patients with swallowing difficulty. Administration with food must be studied carefully because food effects, dose recovery, and coating integrity can affect exposure.

4. Combination adherence package

A commercial package could combine the formulation, oral syringe, dosing calendar, storage system, and laboratory-monitoring support. The packaging and service components may not create drug patent exclusivity, but they can improve differentiation and payer discussions.

5. Regional licensing

A partner with established thalassemia access in the Middle East, South Asia, Southeast Asia, or Mediterranean markets could provide distribution, regulatory, and specialist-network advantages. The most valuable licensing asset would be a formulation with data showing improved acceptance or reduced dosing burden, not an untested excipient concept.

How does Ferriprox compare with competing iron chelators?

Ferriprox competes primarily with deferasirox and deferoxamine. Excipient strategy must account for the different administration profiles of these products.

Product	Active ingredient	Typical administration profile	Formulation opportunity
Ferriprox	Deferiprone	Oral, often divided dosing	Taste, volume, adherence, pediatric dosing
Deferasirox	Deferasirox	Oral once-daily or formulation-dependent dosing	Palatability, dispersibility, gastrointestinal tolerability
Deferoxamine	Deferoxamine	Parenteral infusion	Device simplification and outpatient administration

Ferriprox has an oral route but can require more frequent dosing than once-daily competitors. That creates a disadvantage for routine adherence, while its liquid and tablet options create room for pediatric and flexible weight-based products. A formulation that preserves deferiprone’s oral flexibility while reducing dosing friction could improve its competitive position.

What manufacturing and excipient barriers could protect a follow-on product?

The most defensible manufacturing barriers may involve process control rather than expensive equipment. Important know-how could include:

• Low-oxygen compounding and filling
• Control of trace metals and peroxide impurities
• Reproducible taste-masking coating
• Uniform drug loading in multiparticulates
• High-concentration solution processing
• In-use stability after repeated bottle opening
• Accurate multidose dispensing
• Compatibility with oral syringes
• Control of particle size and dissolution

These process parameters can support trade-secret protection alongside formulation patents. A sponsor that develops a stable product with fewer preservatives, lower excipient burden, and reliable in-use performance may obtain a practical advantage even if competitors can design around individual patent claims.

Key Takeaways

• Ferriprox is deferiprone marketed as 500 mg and 1,000 mg film-coated tablets and a 100 mg/mL oral solution.
• The current oral solution uses glycerol, hydroxyethylcellulose, sodium metabisulfite, and purified water.
• The largest excipient opportunities are taste masking, sulfite-free stability, higher concentration, and pediatric dosing.
• A conventional tablet reformulation has limited commercial and patent value.
• A taste-masked multiparticulate or sulfite-free liquid could support a stronger 505(b)(2) or differentiated-market strategy.
• Stability against oxidation, trace metals, oxygen ingress, and multidose-use conditions is central to product development.
• Generic competition is likely to focus on equivalent immediate-release products, while commercial differentiation is more credible in pediatric and adherence-oriented formats.
• Manufacturing know-how, container-closure engineering, and dosing-device integration can complement formulation patents.
• The best licensing asset would combine formulation data, palatability evidence, stability performance, and a clear regulatory pathway.

FAQs

Can Ferriprox be reformulated without sodium metabisulfite?

Yes, but the replacement must preserve chemical stability, impurity control, shelf life, and in-use performance. A sulfite-free product could have commercial value for patients with sulfite sensitivity.

Is a higher-strength Ferriprox oral solution commercially viable?

Potentially. A higher concentration could reduce daily liquid volume, but taste, viscosity, solubility, precipitation, dosing accuracy, and pediatric acceptability would determine feasibility.

Would a taste-masked Ferriprox product need new clinical trials?

The requirement would depend on the formulation and regulatory pathway. A product with the same strength and exposure may rely on comparative bioavailability and bridging studies, while a modified-release or materially different product could require broader clinical evidence.

Can Ferriprox excipient changes support a new patent?

They can if the formulation provides a specific, non-obvious technical benefit, such as improved stability, reduced bitterness, controlled release, or reliable high-concentration dosing. A simple substitution of standard excipients is less likely to provide strong protection.

Which Ferriprox product concept has the best commercial potential?

A palatable, sulfite-free, high-concentration pediatric liquid with a validated oral syringe has the strongest combined differentiation. It addresses taste, excipient sensitivity, dose volume, and weight-based dosing in one product platform.

References

1. U.S. Food and Drug Administration. (2023). Ferriprox (deferiprone) prescribing information.
2. U.S. Food and Drug Administration. (2024). Applications covered by section 505(b)(2).
3. U.S. Food and Drug Administration. (2024). Orphan drug designation and exclusivity.
4. U.S. Food and Drug Administration. (2024). Inactive ingredient database.
5. European Medicines Agency. (2023). Ferriprox: EPAR product information.